Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Disease Progression

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Docetaxel

Immunomodulating Agents

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Pembrolizumab in Combination with Plinabulin and Docetaxel

Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.

Yan Xu

Yan Xu, Dr.

Mengzhao Wang

A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.

Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)

A Phase 2 Study of Pembrolizumab in Combination With Plinabulin and Docetaxel in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer and Progressive Disease (PD) After Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) Alone or in Combination With Platinum-doublet Chemotherapy (KeyPemls-004)

the time from allocation to the date of death due to any cause.

the time from the first documented evidence of CR or PR until PD or death due to any cause, whichever occurs first, in participants demonstrating CR or PR

the proportion of participants who have achieved a confirmed complete response (CR) or partial response (PR), which is assessed according to RECIST 1.1 criteria.

the time from treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first.

BeyondSpring Pharmaceuticals Inc.

Merck Sharp & Dohme LLC

Peking Union Medical College Hospital

Chief Director of Department of Respiratory and Critical Care Medicine

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)	NCT05599789	Non Small Cell ...	Pembrolizumab i...	18 Years -	Peking Union Medical College Hospital
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)	NCT05599789	Non Small Cell ...	Pembrolizumab i...	18 Years -	Peking Union Medical College Hospital

Spots Global Cancer Trial Database for pembrolizumab in combination with plinabulin and docetaxel